nthly Service Delivery Report (Yembero Health Center)

Hamle Nehase Meskerem

S.No Activity 2011 2011 2012
RMH_FP_C
AR Contraceptive acceptance rate
FP_CAR_A
ge Total new and repeat acceptors, disaggregated by age 79 67 219
FP_CAR_A
ge_New Contraceptive new acceptors by age 45 32 139
FP_CAR_A
ge_New. 1 10 - 14 years
FP_CAR_A
ge_New. 2 15 - 19 years 20 20 30
FP_CAR_A
ge_New. 3 20 - 24 years 17 7 50
FP_CAR_A
ge_New. 4 25 - 29 years 5 3 30
FP_CAR_A
ge_New. 5 30 - 49 years 3 2 29
FP_CAR_A
ge_Rep Contraceptive repeat acceptors by age 34 35 80
FP_CAR_A
ge_Rep. 1 10 - 14 years 10 10
FP_CAR_A
ge_Rep. 2 15 - 19 years 11 19 20
FP_CAR_A
ge_Rep. 3 20 - 24 years 8 4 40
FP_CAR_A
ge_Rep. 4 25 - 29 years 3 2 15
FP_CAR_A
ge_Rep. 5 30 - 49 years 2 5
FP_CAR_M
Td Total new and repeat acceptors, disaggregated by method 79 67 219
FP_CAR_M
td_New Contraceptive new acceptors, by method 45 32 139
FP_CAR_M
td_New. 1 Oral contraceptives 6 26
FP_CAR_M
td_New. 2 Injectables 5 25 102
FP_CAR_M
td_New. 3 Implants 37 1 11
FP_CAR_M
td_New. 4 IUD 3
FP_CAR_M
td_New. 5 Vasectomy
FP_CAR_M
td_New. 6 Tubal ligation
FP_CAR_M
td_New. 7 Others
FP_CAR_M
td_Rep Contraceptive repeat acceptors, by method 34 35 80
FP_CAR_M
td_Rep. 1 Oral contraceptives 32 9 22
FP_CAR_M
td_Rep. 2 Injectables 2 25 35
FP_CAR_M
td_Rep. 3 Implants 1 23
FP_CAR_M
td_Rep. 4 IUD
FP_CAR_M
td_Rep. 5 Vasectomy
FP_CAR_M
td_Rep. 6 Tubal ligation
FP_CAR_M
td_Rep. 7 Others
RMH_FP_I
PPF Immediate Postpartum Contraceptive Acceptance (IPPFP)
RMH_FP_I
PPF Immediate Postpartum Contraceptive Acceptance rate (IPPCAR) 0 0 0
FP_IPPF_A Total Immediate Postpartum Contraceptive acceptors
ge disaggregated by age
FP_IPPF_A
ge. 1 10 - 14 years
FP_IPPF_A
ge. 2 15 - 19 years
FP_IPPF_A
ge. 3 20 - 24 years
FP_IPPF_A
ge. 4 25 - 29 years
FP_IPPF_A
ge. 5 30 - 49 years
FP_IPPF_M Total Immediate Postpartum Contraceptive acceptors
td disaggregated by method
FP_IPPF_M
td. 1 Pills (POP)
FP_IPPF_M
td. 2 Implants
FP_IPPF_M
td. 3 IUD
FP_IPPF_M
td. 4 Tubal ligation
FP_IPPF_M
td. 5 Others
RMH_FP_L
AFPPR Premature Removal of LAFP methods
FP_TtLAFP Total Long acting family planning (LAFP) removal in the reporting
R. period 3
FP_LAFPPR Total number of premature removal of Long acting family planning
_Pre (LAFP) within 6 month insertion 3
FP_LAFPPR
_Pre. 1 Implants 3
FP_LAFPPR
_Pre. 2 IUD
FP_LAFPPR
_Pre. 3 Others
RMH_ANC
_1stV Antenatal Care coverage - First visit
ANC_1stV_ Number of pregnant women who received ANC first visit by
GA.1 gestational week 5 10 71
ANC_1stV_
GA.1. 1 < 16 weeks gestation 10 68
ANC_1stV_
GA.1. 2 >= 16 weeks gestation 5 3
ANC_1stV_ Number of pregnant women that received Antenatal Care (ANC) at
MA least once by maternal age 5 10 71
ANC_1stV_
MA. 1 10 - 14 years 1
ANC_1stV_
MA. 2 15 - 19 years 56
ANC_1stV_
MA. 3 >= 20 years 5 10 14
ANC_4thV Total number of pregnant women that received Antenatal Care
_MA (ANC): at least four visits by maternal age 13 10 27
ANC_4thV
_MA. 1 10 - 14 years
ANC_4thV
_MA. 2 15 - 19 years 8 2 14
ANC_4thV
_MA. 3 >= 20 years 5 8 13
RMH_ANC
_Syph Pregnant women attending antenatal care tested for syphilis
ANC_Syph Total number of pregnant women tested for syphilis 25 10 100
ANC_Syph.
1 Reactive
ANC_Syph.
2 Non-Reactive 25 10 100
ANC_Syph.
RX. Total number of Reactive pregnant women treated for syphilis
RMH_ANC Pregnant women attending antenatal care tested for hepatitis
_Hepa (B&C)
ANC_Hepa Total number of pregnant women tested for Hepatitis (B & C) 25 100
ANC_Hepa
.1 Reactive 25
ANC_Hepa
.2 Non-Reactive 100
ANC_Hepa
_RX. Total number of pregnant women treated for Hepatitis (B&C)
RMH_L&D
_SBA Births attended by skilled health personnel
L&D_SBA.1
. Total number of births attended by skilled health personnel 11 15 38
RMH_L&D
_SBR Still birth rate 0 0 0
L&D_SBR.S
B. Number of still births
L&D_SBR.L
B. Number of Live births 11 15 38
B&D_Ntfc Birth and death notifications
B&D_Ntfc.
1. Number of birth notifications given
B&D_Ntfc.
2. Number of death notifications given
RMH_PNC
_E1stV Early Postnatal Care Coverage
PNC_E1stV
.1 Number of Postnatal visits within 7 days of delivery 11 15 51
PNC_E1stV
.1. 2 24Hrs (1day) 11 15 51
PNC_E1stV
.1. 3 25 - 48 hrs (1 - 2 days)
PNC_E1stV
.1. 4 49 - 72 hrs (2 - 3 days)
PNC_E1stV
.1. 5 73 hrs - 7 days (4 - 7 days)
RMH_L&D
_CS Caesarean section
L&D_CS. Number of women having given birth by caesarean section
Number of women receiving comprehensive abortion care services
RMH_CAC dis aggregated by maternal age 3 0 0
RMH_CAC
_SAC Number of safe abortions performed 3
RMH_CAC
_SAC. 1 10 - 14 years
RMH_CAC
_SAC. 2 15 - 19 years 3
RMH_CAC
_SAC. 3 20 - 24 years
RMH_CAC
_SAC. 4 25 - 29 years
RMH_CAC
_SAC. 5 >= 30 years
RMH_CAC
_PAC Number of post abortion/emergency care
RMH_CAC
_PAC. 1 10 - 14 years
RMH_CAC
_PAC. 2 15 - 19 years
RMH_CAC
_PAC. 3 20 - 24 years
RMH_CAC
_PAC. 4 25 - 29 years
RMH_CAC
_PAC. 5 >= 30 years
 Number of women receiving comprehensive abortion care
RMH_CAC disaggregated by trimester 3
RMH_CAC.
1 First trimester(<12 Weeks) 3
RMH_CAC.
2 Second trimester(>=12 Weeks)
RMH_IMD
_IMMR Institutional maternal deaths
IMD_IMM
R. Number of maternal deaths in health facility
TngP_TPR Total number of teenage girls tested positive for pregnancy 12
TngP_TPR.
1 10 - 14 years 2
TngP_TPR.
2 15 - 19 years 10
RMH_TtP. Total number of women tested positive pregnancy 12
RMH_PMT
CT PMTCT (Prevention of HIV Mother to Child Transmission)
PMTCT_TS Number of pregnant women tested and know their HIV result
T_1. during pregnancy 71
PMTCT_TS Number of pregnant women tested and know their HIV result
T_2. during labour & delivery 18
PMTCT_TS Number of women tested and know their HIV result during the
T_3. postpartum period
Number of women with known HIV positive status attending ANC,
PMTCT_KN delivery and postpartum for new pregnancy linked from Pre ART
pos. and ART
PMTCT_N Number of new HIV positive women during ANC, L&D and
Wpos. Postpartum
The facility provides PMTCT and/or ART service
Percentage of HIV-positive pregnant women who received ART to
RMH_PMT reduce the risk of Women-to child-transmission (MTCT) during
CT_ARV pregnancy, L&D and PNC

PMTCT_AR Number of HIV positive women who received ART to reduce the
V_1. risk of mother to child transmission during ANC for the first time
Number of HIV positive Pregnant women who received ART to
PMTCT_AR reduce the risk of mother to child transmission during L&D for the
V_2. first time
Number of HIV positive lactating women who received ART to
PMTCT_AR reduce the risk of mother to child transmission during PNC for the
V_3. first time
PMTCT_AR Number of HIV-positive women who get pregnant while on ART
V_4. and linked to ANC
Total number of infants within 12 months received virological test
result 0 0 0
PMTCT_IP Number of HIV exposed infants who received a virological HIV test
CR.1 0-2 Months of birth
PMTCT_IP
CR.1. 1 Positive
PMTCT_IP
CR.1. 2 Negative
PMTCT_IP Number of HIV exposed infants who received a virological HIV test
CR.1.2 2-12 Months of birth
PMTCT_IP
CR.1.2. 1 Positive
PMTCT_IP
CR.1.2. 2 Negative
RMH_PMT Percentage of Infants born to HIV-infected women started on co-
CT_ICPT trimoxazole prophylaxis within two months of birth
PMTCT_IC Number of infants born to HIV positive women started on co-
PT.1. trimoxazole prophylaxis within two months of birth
Percentage of Infants born to HIV-infected women receiving
RMH_PMT antiretroviral (ARV) prophylaxis for prevention of Women-to-child
CT_IARV transmission (PMTCT)
PMTCT_IA Number of HIV exposed infants who received ARV prophylaxis For 6
RV_1. weeks
PMTCT_IA Number of HIV exposed infants who received ARV prophylaxis For
RV_2. 12 weeks
RMH_L&D
_pos. Number of HIV positive women who gave birth at health institution
RMH_PMT
CT_PRN_T Percentage of partners of pregnant, laboring and lactating women
ST tested for HIV
PMTCT_PR Number of partners of pregnant, laboring and lactating women
N_TST. tested for HIV and know their results
PMTCT_PR Number of partners of pregnant, laboring and lactating women
N_Pos. whose test result is HIV positive
RMH_PMT Number of HIV exposed infants receiving HIV confirmatory
CT_IABT (antibody test) by 18 months
RMH_PMT
CT_IABT. 1 Positive
RMH_PMT
CT_IABT. 2 Negative
NCH_EPI Expanded Program of Immunization (EPI)
Number of children under one year of age who have received BCG
EPI_BCG. vaccine 25 47
EPI_Penta Number of children under one year of age who have received first
1. dose of pentavalent vaccine 39 30 37
EPI_Penta Number of children under one year of age who have received third
3. dose of pentavalent vaccine 33 19 34
Number of children under one year of age who have received first
EPI_PCV1. dose of pneumococcal vaccine 39 30 37
Number of children under one year of age who have received third
EPI_PCV3. dose of pneumococcal vaccine 33 19 34
Number of children under one year of age who have received first
EPI_PV1. dose of polio vaccine 39 30 37
Number of children under one year of age who have received third
EPI_PV3. dose of Polio vaccine 33 19 34
Number of children under one year of age who have received one
EPI_IPV. dose of inactivated polio vaccine 33 19 9
 Number of children under one year of age who have received first
EPI_RT1. dose of Rotavirus vaccine 39 30 37
Number of children under one year of age who have received 2nd
EPI_RT2. dose of Rotavirus vaccine 29 25 34
Number of children under one year of age who have received first
EPI_MCV1. dose of measles vaccine 17 16 4

EPI_FI. Number of children received all vaccine doses before 1st birthday 17 16 4
Number of children under two years of age who have received
EPI_MCV2. second dose of measles vaccine
Number of Infants whose mothers had protective doses of TT
EPI_PAB. against NNT (PAB) 39 30 71
EPI_HPV HPV Vaccination
Number of girls 14 year of age who have received first dose of
EPI_HPV1. human papilloma virus vaccine
Number of girls 14 years of age who have received second dose of
human papillomavirus vaccine in 6 month interval from the first
EPI_HPV2. dose
RMH_MV_
TT TT Vaccination
MV_TT1. Number of women who have received TT1 vaccination 25 61
MV_TT2. Number of women who have received TT2 vaccination 16 42
MV.TT3. Number of women who have received TT3 vaccination 21 30
MV.TT4. Number of women who have received TT4 vaccination 10
MV.TT5.. Number of women who have received TT5 vaccination 5
HCSM_EPI
_VWR Vaccine Wastage Rate
VWR_BCG BCG Vaccine wastage rate 28.6 35.6
VWR_BCG
_giv. BCG doses given (all ages) 25 47
VWR_BCG
_opn. BCG doses opened 30 60
VWR_BCG
_dam. BCG doses damaged 5 13
VWR_BCG
_dis. BCG doses expired
VWR_Pent
a Penta Vaccine wastage rate 0 0 0
VWR_Pent
a_giv. Pentavalent (DPT-HepB-Hib) doses given (all ages) 101 74 103
VWR_Pent
a_opn. Pentavalent (DPT-HepB-Hib) doses opened 101 74 103
VWR_Pent
a_dam. Pentavalent (DPT-HepB-Hib) doses damaged
VWR_Pent
a_dis. Pentavalent (DPT-HepB-Hib) doses expired
VWR_PCV PCV Vaccine wastage rate 1.9 0 0
VWR_PCV
_giv. Pneumococcal conjugated vaccine doses given (all ages) 101 74 71
VWR_PCV
_opn. Pneumococcal conjugated vaccine doses opened 102 74 71
VWR_PCV
_dam. Pneumococcal conjugated vaccine doses damaged 1
VWR_PCV
_dis. Pneumococcal conjugated vaccine doses expired
Rota Vaccine wastage rate 0 0 0
VWR_RT_g
iv. Rota doses give (all ages) 68 55 71
VWR_RT_o
pn. Rota doses opened 68 55 71
VWR_RT_d
am. Rota doses damaged
VWR_RT_d
is. Rota doses expired
VWR_PV Polio Vaccine wastage rate 0 14 20.2
VWR_PV_g
iv. Polio doses given (all ages) 100 74 71
VWR_PV_
opn. Polio doses opened 100 80 80
VWR_PV_
dam. Polio doses damaged 6 9
VWR_PV_
dis. Polio doses expired
VWR_MCV Measles Vaccine wastage rate 26.1 33.3 75
VWR_MCV
_giv. Measles doses given (all ages) 17 16 4
VWR_MCV
_opn. Measles doses opened 20 20 10
VWR_MCV
_dam. Measles doses damaged 3 4 6
VWR_MCV
_dis. Measles doses expired
TT Vaccine wastage rate 20.5 2.6
VWR_TT_o
pn. TT doses given 62 148
VWR_TT_g
iv. TT doses opened 70 150
VWR_TT_d
am. TT doses damaged 8 2
VWR_TT_d
is. TT doses expired
VWR_IPV IPV Vaccine wastage rate 29.8 9.5 18.2
VWR_IPV_
giv. IPV doses given 33 19 9
VWR_IPV_
opn. IPV doses opened 40 20 10
VWR_IPV_
dam. IPV doses damaged 7 1 1
VWR_IPV_
dis. IPV doses expired
VWR_HPV HPV Vaccine wastage rate
VWR_HPV
_giv. HPV doses given
VWR_HPV
_opn. HPV doses opened
VWR_HPV
_dam. HPV doses damaged
VWR_HPV
_dis. HPV doses expired
NCH_CHIM
_EIND Early institutional neonatal death
NCH_CHIM
_EIND Early Institutional Neonatal Death Rate
NCH_CHIM
_EIND Number of neonatal deaths in the first 7 days of life(Institutional)
NCH_CHIM
_EIND. 1 First 24 hrs of life
NCH_CHIM
_EIND. 2 1-7 days of life
NCH_CHIM
_PnRX Under-five children with pneumonia received antibiotic treatment
CHIM_PnR
X. Number of under 5 children treated for pneumonia 143
NCH_CHIM
_VSD Number of sick young infants 0-2 months treated for sepsis
CHIM_VSD
_sep. Number of sick young infants 0-2 months treated for sepsis 1
CHIM_VSD Number of sick young infants 0-2 months treated for local bacterial
_lbi. infection (LBI) 1
NCH_CHIM
_DhRX Proportion of children who are treated for Diarrhea

CHIM_DhR
X_orszinc. Number of children treated for diarrhea with ORS and zinc 25 79

CHIM_DhR
X_orsonly. Number of children treated for diarrhea with ORS only 5 3 82
NCH_CHIM Proportion of low birth weight and/or premature newborns for
_KMC whom KMC was initiated after delivery
CHIM_KM Total number of newborns weighing <2000gm and/or premature
C.1. newborns for which KMC initiated
CHIM_E4K
MC. Total number of newborns weighing <2000gm and/or premature
NCH_CHIM Asphyxiated neonates who were resuscitated (with bag & mask)
_AsfxRS and survived
CHIM_Asfx
RS. Total number of neonates resuscitated and survived
CHIM_Asfx
R. Total number of neonates resuscitated
NCH_NTR Maternal and Child Nutrition
NCH_NTR_
LBW Percentage of low birth weight (LBW) newborns 0 0 0
NTR_LBW_
1. Number of live-born babies with birth weight less than 2500 gm
NTR_LBW_
2. Total number of live births weighed 11 15 18
NCH_NTR_
GMP Promotion of GMP participation among children under 2 yr

NTR_GMP Number of children less than 2 years weighted during GMP session 575 697 650
NTR_GMP.
1 0 - 5 months 32 43 251
NTR_GMP.
2 6 - 23 months 543 654 399
NTR_GMP Number of weights recorded with moderate malnutrition by age (Z
_MM score b/n -2 & -3)
NTR_GMP
_MM. 1 0 - 5 months
NTR_GMP
_MM. 2 6 - 23 months
Number of weights recorded with severe malnutrition by age ( Z
GMP_SM score below -3)
GMP_SM.
1 0 - 5 months
GMP_SM.
2 6 - 23 months

NTR_S4AM Children aged <5 yr screened for acute malnutrition

NTR_S4AM Total number of children <5yrs screened for acute malnutrition 686 597 650
NTR_S4AM
.1 0 - 5 months 32 54 251
NTR_S4AM
.2 6 - 59 months 654 543 399
S4AM_MA Number of children <5 year screened and have moderate acute
M malnutrition 6
S4AM_MA
M. 1 0 - 5 months
S4AM_MA
M. 2 6 - 59 months 6
S4AM_SA Number of children <5 year screened and have severe acute
M malnutrition 1 6 3
S4AM_SA
M. 1 0 - 5 months
S4AM_SA
M. 2 6 - 59 months 1 6 3
NCH_NTR_ Treatment outcome for management of severe acute malnutrition
SAM_RXO in children under 5 yr (OTP and SC)
NTR_SAM_ Treatment outcome for management of SAM in children under 5
RXO_1 years 7
NTR_SAM_
RXO_1. 1 Recovered 7
NTR_SAM_
RXO_1. 2 Died
NTR_SAM_
RXO_1. 3 Transferred out
NTR_SAM_
RXO_1. 4 Defaulted
NTR_SAM_
RXO_1. 5 Non-respondent
NTR_SAM_
RXO_1. 6 Medical transfer
NTR_SAM_
RXO_1. 7 Unknown status
NTR_SAM_ Number of children who exit from severe acute malnutrition
Ext. treatment during the reporting period 7
NTR_SAM_ Number of children with SAM admitted to TFP(OTP &SC) during the
Adt. reporting period 3
NTR_VAS_ Total number of children aged 6-59 months who received Vitamin A
1 supplementation - by age 5 1 370
NTR_VAS_
1. 1 6 - 11 months 76
NTR_VAS_
1. 2 12 - 59 months 5 1 294
NTR_VAS_ Total number of children aged 6-59 months who received Vitamin A
2 supplementation - by dose 5 1 370
NTR_VAS_
2. 1 First dose 5 1 370
NTR_VAS_
2. 2 Second dose
NTR_DWR Total number of children aged 24 - 59 months dewormed 6 1 2
NTR_DWR.
1 First dose 6 1 2
NTR_DWR.
2 Second dose
PLW_S4A
M Total number of PLW screened for acute malnutrition 61 95 121
PLW_S4A
M. 1 MUAC < 23 cm 25 40 57
PLW_S4A
M. 2 MUAC >= 23 cm 36 55 64

ANC_IFA Total number of Pregnant women received IFA at least 90 plus

ANC_IFA. 1 10 - 14 years

ANC_IFA. 2 15 - 19 years

ANC_IFA. 3 >= 20 years

RMH_ANC
_DWR. Number of pregnant women de-wormed
CDC_HIV HIV/AIDS
Number of individuals who have been tested for HIV and received
HIV_HCT.1 their results
HIV_VCT Clients receiving HIV test results at VCT 334
HIV_VCT. 1 < 1 year, Male

HIV_VCT. 2 < 1 year, Female

HIV_VCT. 3 1 - 4 years, Male

HIV_VCT. 4 1 - 4 years, Female

HIV_VCT. 5 5 - 9 years, Male

HIV_VCT. 6 5 - 9 years, Female

HIV_VCT. 7 10 - 14 years, Male

HIV_VCT. 8 10 - 14 years, Female

HIV_VCT. 9 15 - 19 years, Male 18

HIV_VCT.
10 15 - 19 years, Female 29
HIV_VCT.
11 20 - 24 years, Male 45
HIV_VCT.
12 20 - 24 years, Female 61
HIV_VCT.
13 25 - 49 years, Male 89
HIV_VCT.
14 25 - 49 years, Female 92
HIV_VCT.
15 >= 50 years, Male
HIV_VCT.
16 >= 50 years, Female
HIV_VCT_P
os.1 Clients testing positive for HIV at VCT
HIV_VCT_P
os.1. 1 < 1 year, Male
HIV_VCT_P
os.1. 2 < 1 year, Female
HIV_VCT_P
os.1. 3 1 - 4 years, Male
HIV_VCT_P
os.1. 4 1 - 4 years, Female
HIV_VCT_P
os.1. 5 5 - 9 years, Male
HIV_VCT_P
os.1. 6 5 - 9 years, Female
HIV_VCT_P
os.1. 7 10 - 14 years, Male
HIV_VCT_P
os.1. 8 10 - 14 years, Female
HIV_VCT_P
os.1. 9 15 - 19 years, Male
HIV_VCT_P
os.1. 10 15 - 19 years, Female
HIV_VCT_P
os.1. 11 20 - 24 years, Male
HIV_VCT_P
os.1. 12 20 - 24 years, Female
HIV_VCT_P
os.1. 13 25 - 49 years, Male
HIV_VCT_P
os.1. 14 25 - 49 years, Female
HIV_VCT_P
os.1. 15 >= 50 years, Male
HIV_VCT_P
os.1. 16 >= 50 years, Female
HIV_PITC Clients receiving HIV test results at PITC 125
HIV_PITC.
1 < 1 year, Male
HIV_PITC.
2 < 1 year, Female
HIV_PITC.
3 1 - 4 years, Male
HIV_PITC.
4 1 - 4 years, Female
HIV_PITC.
5 5 - 9 years, Male
HIV_PITC.
6 5 - 9 years, Female
HIV_PITC.
7 10 - 14 years, Male
HIV_PITC.
8 10 - 14 years, Female
HIV_PITC.
9 15 - 19 years, Male
HIV_PITC.
10 15 - 19 years, Female 18
HIV_PITC.
11 20 - 24 years, Male 12
HIV_PITC.
12 20 - 24 years, Female 22
HIV_PITC.
13 25 - 49 years, Male 14
HIV_PITC.
14 25 - 49 years, Female 59
HIV_PITC.
15 >= 50 years, Male
HIV_PITC.
16 >= 50 years, Female
HIV_PITC_
Pos Clients testing positive for HIV at PITC
HIV_PITC_
Pos. 1 < 1 year, Male
HIV_PITC_
Pos. 2 < 1 year, Female
HIV_PITC_
Pos. 3 1 - 4 years, Male
HIV_PITC_
Pos. 4 1 - 4 years, Female
HIV_PITC_
Pos. 5 5 - 9 years, Male
HIV_PITC_
Pos. 6 5 - 9 years, Female
HIV_PITC_
Pos. 7 10 - 14 years, Male
HIV_PITC_
Pos. 8 10 - 14 years, Female
HIV_PITC_
Pos. 9 15 - 19 years, Male
HIV_PITC_
Pos. 10 15 - 19 years, Female
HIV_PITC_
Pos. 11 20 - 24 years, Male
HIV_PITC_
Pos. 12 20 - 24 years, Female
HIV_PITC_
Pos. 13 25 - 49 years, Male
HIV_PITC_
Pos. 14 25 - 49 years, Female
HIV_PITC_
Pos. 15 >= 50 years, Male
HIV_PITC_
Pos. 16 >= 50 years, Female
HIV_HCT_P
G HCT by population group
HIV_HCT_P
G.1. Female commercial Sex workers - received result
HIV_HCT_P
G.1.1. Female commercial Sex workers - tested positive
HIV_HCT_P
G.2. Long distance drivers - received result
HIV_HCT_P
G.2.1. Long distance drivers - tested positive
HIV_HCT_P
G.3. Mobile/Daily Laborers - received result
HIV_HCT_P
G.3.1. Mobile/Daily Laborers - tested positive
HIV_HCT_P
G.4. OVC - received result
HIV_HCT_P
G.4.1. OVC - tested positive
HIV_HCT_P
G.5. Children of PLHIV - received result
HIV_HCT_P
G.5.1. Children of PLHIV - tested positive
HIV_HCT_P
G.6. Prisoners - received result
HIV_HCT_P
G.6.1. Prisoners - tested positive
HIV_HCT_P
G.7. Partners of PLHIV - received result
HIV_HCT_P
G.7.1. Partners of PLHIV - tested positive
HIV_HCT_P
G.8. Other MARPs - received result
HIV_HCT_P
G.8.1. Other MARPs - tested positive
HIV_HCT_P
G.9. HCT in general population - received result 459
HIV_HCT_P
G.9.1. HCT in general population - tested positive
CDC_STI_P
ITC STI Cases Tested for HIV in the Reporting Period
STI_PITC Number of STI cases tested for HIV

STI_PITC. 1 Positive, Male

STI_PITC. 2 Positive, Female

STI_PITC. 3 Negative, Male

STI_PITC. 4 Negative, Female

CDC_STI Total number of STI cases by sex
CDC_STI. 1 Male
CDC_STI. 2 Female
CDC_STI_S
y Total number of STI cases by syndrome
CDC_STI_S
y. 1 Urethral discharge
CDC_STI_S
y. 2 Persistent urethral discharge
CDC_STI_S
y. 3 Scrotal swelling
CDC_STI_S
y. 4 Vaginal discharge
CDC_STI_S
y. 5 PID (pelvic inflammatory disease)
CDC_STI_S
y. 6 Non vesicular genital ulcer disease (NVGUD)
CDC_STI_S
y. 7 Vesicular genital ulcer disease (VGUD)
CDC_STI_S
y. 8 Inguinal bubo
CDC_STI_S
y. 9 Neonatal conjunctivitis
CDC_STI_S
y. 10 Neonatal herpes
Number of adults and children who are currently on ART 0 0 0
Number of adults who are currently on ART by regimen type 0 0 0
HIV_RXC.1.
1.1 Adult aged 15-19 yrs currently on ART 0 0 0
HIV_RXC.1.
1.1.1 Adult 15-19 years currently on ART on first line regimen
HIV_RXC.1.
1.1.1. 1 1c = AZT-3TC-NVP, Male
HIV_RXC.1.
1.1.1. 2 1c = AZT-3TC-NVP, Female
HIV_RXC.1.
1.1.1. 3 1d = AZT-3TC-EFV, Male
HIV_RXC.1.
1.1.1. 4 1d = AZT-3TC-EFV, Female
HIV_RXC.1.
1.1.1. 5 1e = TDF-3TC-EFV, Male
HIV_RXC.1.
1.1.1. 6 1e = TDF-3TC-EFV, Female
HIV_RXC.1.
1.1.1. 7 1f= TDF + 3TC+ NVP, Male
HIV_RXC.1.
1.1.1. 8 1f= TDF + 3TC+ NVP, Female
HIV_RXC.1.
1.1.1. 9 1g= ABC + 3TC + EFV, Male
HIV_RXC.1.
1.1.1. 10 1g= ABC + 3TC + EFV, Female
HIV_RXC.1.
1.1.1. 11 1h= ABC + 3TC NVP, Male
HIV_RXC.1.
1.1.1. 12 1h= ABC + 3TC NVP, Female
HIV_RXC.1.
1.1.1. 13 Others, Male
HIV_RXC.1.
1.1.1. 14 Others, Female
HIV_RXC.1.
1.1.1. 15 1j=TDF + 3TC + DTG, Male
HIV_RXC.1.
1.1.1. 16 1j=TDF + 3TC + DTG, Female
HIV_RXC.1.
1.1.1. 17 1k= AZT +3TC +DTG, Male
HIV_RXC.1.
1.1.1. 18 1k= AZT +3TC +DTG, Female
HIV_RXC.1.
1.1.1.2 Adult 15-19 years currently on ART on second line regimen
HIV_RXC.1.
1.1.1.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.
1.1.1.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.
1.1.1.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.
1.1.1.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.
1.1.1.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.
1.1.1.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.
1.1.1.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.
1.1.1.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.
1.1.1.2. 9 2i = ABC + 3TC + LPV/r, Male

HIV_RXC.1.
1.1.1.2. 10 2i = ABC + 3TC + LPV/r, Female

HIV_RXC.1.
1.1.1.2. 11 Others, Male

HIV_RXC.1.
1.1.1.2. 12 Others, Female
HIV_RXC.1.
1.1.1.3 Adult 15-19 years currently on ART on third line regimen
HIV_RXC.1.
1.1.1.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.
1.1.1.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.
1.1.1.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.
1.1.1.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.
1.1.1.3. 5 Others, Male
HIV_RXC.1.
1.1.1.3. 6 Others, Female
HIV_RXC.1.
1.1.1.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.
1.1.1.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female
HIV_RXC.1.
1.2 Adult aged 20-24 yrs currently on ART 0 0 0
HIV_RXC.1.
1.2.1 Adult 20-24 years currently on ART on first line regimen
HIV_RXC.1.
1.2.1. 1 1c = AZT-3TC-NVP, Male
HIV_RXC.1.
1.2.1. 2 1c = AZT-3TC-NVP, Female
HIV_RXC.1.
1.2.1. 3 1d = AZT-3TC-EFV, Male
HIV_RXC.1.
1.2.1. 4 1d = AZT-3TC-EFV, Female
HIV_RXC.1.
1.2.1. 5 1e = TDF-3TC-EFV, Male
HIV_RXC.1.
1.2.1. 6 1e = TDF-3TC-EFV, Female
HIV_RXC.1.
1.2.1. 7 1f= TDF + 3TC+ NVP, Male
HIV_RXC.1.
1.2.1. 8 1f= TDF + 3TC+ NVP, Female
HIV_RXC.1.
1.2.1. 9 1g= ABC + 3TC + EFV, Male
HIV_RXC.1.
1.2.1. 10 1g= ABC + 3TC + EFV, Female
HIV_RXC.1.
1.2.1. 11 1h= ABC + 3TC NVP, Male
HIV_RXC.1.
1.2.1. 12 1h= ABC + 3TC NVP, Female
HIV_RXC.1.
1.2.1. 13 Others, Male
HIV_RXC.1.
1.2.1. 14 Others, Female
HIV_RXC.1.
1.2.1. 15 1j=TDF + 3TC + DTG, Male
HIV_RXC.1.
1.2.1. 16 1j=TDF + 3TC + DTG, Female
HIV_RXC.1.
1.2.1. 17 1k= AZT +3TC +DTG, Male
HIV_RXC.1.
1.2.1. 18 1k= AZT +3TC +DTG, Female
HIV_RXC.1.
1.2.2 Adult 20-24 years currently on ART on second line regimen
HIV_RXC.1.
1.2.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.
1.2.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.
1.2.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.
1.2.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.
1.2.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.
1.2.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.
1.2.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.
1.2.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.
1.2.2. 9 2i = ABC + 3TC + LPV/r, Male
HIV_RXC.1.
1.2.2. 10 2i = ABC + 3TC + LPV/r, Female
HIV_RXC.1.
1.2.2. 11 Others, Male
HIV_RXC.1.
1.2.2. 12 Others, Female
HIV_RXC.1.
1.2.3 Adult 20-24 years currently on ART on third line regimen
HIV_RXC.1.
1.2.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.
1.2.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.
1.2.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.
1.2.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.
1.2.3. 5 Others, Male
HIV_RXC.1.
1.2.3. 6 Others, Female
HIV_RXC.1.
1.2.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.
1.2.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female
HIV_RXC.1.
1.3 Adult aged 25-49 yrs currently on ART 0 0 0
HIV_RXC.1.
1.3.1 Adult 25-49 years currently on ART on first line regimen
HIV_RXC.1.
1.3.1. 1 1c = AZT-3TC-NVP, Male
HIV_RXC.1.
1.3.1. 2 1c = AZT-3TC-NVP, Female
HIV_RXC.1.
1.3.1. 3 1d = AZT-3TC-EFV, Male
HIV_RXC.1.
1.3.1. 4 1d = AZT-3TC-EFV, Female
HIV_RXC.1.
1.3.1. 5 1e = TDF-3TC-EFV, Male
HIV_RXC.1.
1.3.1. 6 1e = TDF-3TC-EFV, Female
HIV_RXC.1.
1.3.1. 7 1f= TDF + 3TC+ NVP, Male
HIV_RXC.1.
1.3.1. 8 1f= TDF + 3TC+ NVP, Female
HIV_RXC.1.
1.3.1. 9 1g= ABC + 3TC + EFV, Male
HIV_RXC.1.
1.3.1. 10 1g= ABC + 3TC + EFV, Female
HIV_RXC.1.
1.3.1. 11 1h= ABC + 3TC NVP, Male
HIV_RXC.1.
1.3.1. 12 1h= ABC + 3TC NVP, Female
HIV_RXC.1.
1.3.1. 13 Others, Male
HIV_RXC.1.
1.3.1. 14 Others, Female
HIV_RXC.1.
1.3.1. 15 1j=TDF + 3TC + DTG, Male
HIV_RXC.1.
1.3.1. 16 1j=TDF + 3TC + DTG, Female
HIV_RXC.1.
1.3.1. 17 1k= AZT +3TC +DTG, Male
HIV_RXC.1.
1.3.1. 18 1k= AZT +3TC +DTG, Female
HIV_RXC.1.
1.3.2 Adult 25-49 years currently on ART on second line regimen
HIV_RXC.1.
1.3.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.
1.3.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.
1.3.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.
1.3.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.
1.3.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.
1.3.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.
1.3.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.
1.3.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.
1.3.2. 9 2i = ABC + 3TC + LPV/r, Male
HIV_RXC.1.
1.3.2. 10 2i = ABC + 3TC + LPV/r, Female
HIV_RXC.1.
1.3.2. 11 Others, Male
HIV_RXC.1.
1.3.2. 12 Others, Female
HIV_RXC.1.
1.3.3 Adult 25-49 years currently on ART on third line regimen
HIV_RXC.1.
1.3.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.
1.3.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.
1.3.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.
1.3.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.
1.3.3. 5 Others, Male
HIV_RXC.1.
1.3.3. 6 Others, Female
HIV_RXC.1.
1.3.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.
1.3.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female
HIV_RXC.1.
1.4 Adult aged 50+ yrs currently on ART 0 0 0
HIV_RXC.1.
1.4.1 Adult >=50 years currently on ART on first line regimen
HIV_RXC.1.
1.4.1. 1 1c = AZT-3TC-NVP, Male
HIV_RXC.1.
1.4.1. 2 1c = AZT-3TC-NVP, Female
HIV_RXC.1.
1.4.1. 3 1d = AZT-3TC-EFV, Male
HIV_RXC.1.
1.4.1. 4 1d = AZT-3TC-EFV, Female
HIV_RXC.1.
1.4.1. 5 1e = TDF-3TC-EFV, Male
HIV_RXC.1.
1.4.1. 6 1e = TDF-3TC-EFV, Female
HIV_RXC.1.
1.4.1. 7 1f= TDF + 3TC+ NVP, Male
HIV_RXC.1.
1.4.1. 8 1f= TDF + 3TC+ NVP, Female
HIV_RXC.1.
1.4.1. 9 1g= ABC + 3TC + EFV, Male
HIV_RXC.1.
1.4.1. 10 1g= ABC + 3TC + EFV, Female
HIV_RXC.1.
1.4.1. 11 1h= ABC + 3TC NVP, Male
HIV_RXC.1.
1.4.1. 12 1h= ABC + 3TC NVP, Female
HIV_RXC.1.
1.4.1. 13 Others, Male
HIV_RXC.1.
1.4.1. 14 Others, Female
HIV_RXC.1.
1.4.1. 15 1j=TDF + 3TC + DTG, Male
HIV_RXC.1.
1.4.1. 16 1j=TDF + 3TC + DTG, Female
HIV_RXC.1.
1.4.1. 17 1k= AZT +3TC +DTG, Male
HIV_RXC.1.
1.4.1. 18 1k= AZT +3TC +DTG, Female
HIV_RXC.1.
1.4.2 Adult >=50 years currently on ART on second line regimen
HIV_RXC.1.
1.4.2. 1 2e= AZT+3TC+LPV/r, Male
HIV_RXC.1.
1.4.2. 2 2e= AZT+3TC+LPV/r, Female
HIV_RXC.1.
1.4.2. 3 2f=AZT+3TC+ATV/r, Male
HIV_RXC.1.
1.4.2. 4 2f=AZT+3TC+ATV/r, Female
HIV_RXC.1.
1.4.2. 5 2g= TDF-3TC-LPV/r, Male
HIV_RXC.1.
1.4.2. 6 2g= TDF-3TC-LPV/r, Female
HIV_RXC.1.
1.4.2. 7 2h =TDF-3TC-ATV/r, Male
HIV_RXC.1.
1.4.2. 8 2h =TDF-3TC-ATV/r, Female
HIV_RXC.1.
1.4.2. 9 2i = ABC + 3TC + LPV/r, Male
HIV_RXC.1.
1.4.2. 10 2i = ABC + 3TC + LPV/r, Female
HIV_RXC.1.
1.4.2. 11 Others, Male
HIV_RXC.1.
1.4.2. 12 Others, Female
HIV_RXC.1.
1.4.3 Adult >=50 years currently on ART on third line regimen
HIV_RXC.1.
1.4.3. 1 3a=DRV/r+DTG+AZT/3TC, Male
HIV_RXC.1.
1.4.3. 2 3a=DRV/r+DTG+AZT/3TC, Female
HIV_RXC.1.
1.4.3. 3 3b=DRV/r+DTG+TDF/3TC, Male
HIV_RXC.1.
1.4.3. 4 3b=DRV/r+DTG+TDF/3TC, Female
HIV_RXC.1.
1.4.3. 5 Others, Male
HIV_RXC.1.
1.4.3. 6 Others, Female
HIV_RXC.1.
1.4.3. 7 3d= DRV/r + ABC + EFV + 3TC, Male
HIV_RXC.1.
1.4.3. 8 3d= DRV/r + ABC + EFV + 3TC, Female
Number of children who are currently on ART by regimen type 0 0 0
HIV_RXC.1.
2.1 Children aged <1 yr currently on ART 0 0 0
HIV_RXC.1.
2.1.1 Infants <1 years currently on ART on First Line Regimen
HIV_RXC.1.
2.1.1. 1 4c = AZT-3TC-NVP, Male
HIV_RXC.1.
2.1.1. 2 4c = AZT-3TC-NVP, Female
HIV_RXC.1.
2.1.1. 3 4f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.1.1. 4 4f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.1.1. 5 4g=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.1.1. 6 4g=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.1.1. 7 Others, Male
HIV_RXC.1.
2.1.1. 8 Others, Female
HIV_RXC.1.
2.1.2 Infants <1 years currently on ART on second line regimen
HIV_RXC.1.
2.1.2. 1 5e=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.1.2. 2 5e=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.1.2. 3 5f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.1.2. 4 5f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.1.2. 5 5j=ABC+ 3TC+ LPV/r, Male
HIV_RXC.1.
2.1.2. 6 5j=ABC+ 3TC+ LPV/r, Female
HIV_RXC.1.
2.1.2. 7 Others, Male
HIV_RXC.1.
2.1.2. 8 Others, Female
HIV_RXC.1.
2.1.2. 9 5k= RAL + AZT + 3TC, Male
HIV_RXC.1.
2.1.2. 10 5k= RAL + AZT + 3TC, Female
HIV_RXC.1.
2.1.2. 11 5l= RAL + ABC + 3TC, Male
HIV_RXC.1.
2.1.2. 12 5l= RAL + ABC + 3TC, Female
HIV_RXC.1.
2.2 Children aged 1-4 yrs currently on ART 0 0 0
HIV_RXC.1.
2.2.1 Children 1 - 4 years currently on ART on first line regimen
HIV_RXC.1.
2.2.1. 1 4c = AZT-3TC-NVP, Male
HIV_RXC.1.
2.2.1. 2 4c = AZT-3TC-NVP, Female
HIV_RXC.1.
2.2.1. 3 4d = AZT-3TC-EFV, Male
HIV_RXC.1.
2.2.1. 4 4d = AZT-3TC-EFV, Female
HIV_RXC.1.
2.2.1. 5 4f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.2.1. 6 4f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.2.1. 7 4g=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.2.1. 8 4g=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.2.1. 9 Others, Male
HIV_RXC.1.
2.2.1. 10 Others, Female
HIV_RXC.1.
2.2.1. 11 4j= ABC +3TC + DTG, Male
HIV_RXC.1.
2.2.1. 12 4j= ABC +3TC + DTG, Female
HIV_RXC.1.
2.2.1. 13 4k= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.2.1. 14 4k= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.2.1. 15 4l= ABC + 3TC + EFV, Male
HIV_RXC.1.
2.2.1. 16 4l= ABC + 3TC + EFV, Female
HIV_RXC.1.
2.2.2 Children 1 - 4 years currently on ART on second line regimen
HIV_RXC.1.
2.2.2. 1 5e=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.2.2. 2 5e=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.2.2. 3 5f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.2.2. 4 5f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.2.2. 5 5h=ABC + 3TC + EFV, Male
HIV_RXC.1.
2.2.2. 6 5h=ABC + 3TC + EFV, Female
HIV_RXC.1.
2.2.2. 7 5j=ABC+ 3TC+ LPV/r, Male
HIV_RXC.1.
2.2.2. 8 5j=ABC+ 3TC+ LPV/r, Female
HIV_RXC.1.
2.2.2. 9 Others, Male
HIV_RXC.1.
2.2.2. 10 Others, Female
HIV_RXC.1.
2.2.2. 11 5k= RAL + AZT + 3TC, Male
HIV_RXC.1.
2.2.2. 12 5k= RAL + AZT + 3TC, Female
HIV_RXC.1.
2.2.2. 13 5l= RAL + ABC + 3TC, Male
HIV_RXC.1.
2.2.2. 14 5l= RAL + ABC + 3TC, Female
HIV_RXC.1.
2.2.2. 15 5m = ABC + 3TC + DTG, Male
HIV_RXC.1.
2.2.2. 16 5m = ABC + 3TC + DTG, Female
HIV_RXC.1.
2.2.2. 17 5n= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.2.2. 18 5n= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.2.3 Children 1 - 4 years currently on ART on third line regimen
HIV_RXC.1.
2.2.3. 1 6a=DRV/r+RAL+AZT+3TC, Male
HIV_RXC.1.
2.2.3. 2 6a=DRV/r+RAL+AZT+3TC, Female
HIV_RXC.1.
2.2.3. 3 6b=DRV/r+RAL+TDF+3TC, Male
HIV_RXC.1.
2.2.3. 4 6b=DRV/r+RAL+TDF+3TC, Female
HIV_RXC.1.
2.2.3. 5 Others, Male
HIV_RXC.1.
2.2.3. 6 Others, Female
HIV_RXC.1.
2.2.3. 7 6c=DRV/r+DTG+AZT+3TC, Male
HIV_RXC.1.
2.2.3. 8 6c=DRV/r+DTG+AZT+3TC, Female
HIV_RXC.1.
2.2.3. 9 6f= DRV/r + DTG + ABC + 3TC, Male
HIV_RXC.1.
2.2.3. 10 6f= DRV/r + DTG + ABC + 3TC, Female
HIV_RXC.1.
2.3 Children aged 5-9 yrs currently on ART 0 0 0
HIV_RXC.1.
2.3.1 Children 5 - 9 years currently on ART on first line regimen
HIV_RXC.1.
2.3.1. 1 4c = AZT-3TC-NVP, Male
HIV_RXC.1.
2.3.1. 2 4c = AZT-3TC-NVP, Female
HIV_RXC.1.
2.3.1. 3 4d = AZT-3TC-EFV, Male
HIV_RXC.1.
2.3.1. 4 4d = AZT-3TC-EFV, Female
HIV_RXC.1.
2.3.1. 5 4e= TDF-3TC-EFV, Male
HIV_RXC.1.
2.3.1. 6 4e= TDF-3TC-EFV, Female
HIV_RXC.1.
2.3.1. 7 4f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.3.1. 8 4f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.3.1. 9 4g=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.3.1. 10 4g=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.3.1. 11 Others, Male
HIV_RXC.1.
2.3.1. 12 Others, Female
HIV_RXC.1.
2.3.1. 15 4j= ABC +3TC + DTG, Male
HIV_RXC.1.
2.3.1. 16 4j= ABC +3TC + DTG, Female
HIV_RXC.1.
2.3.1. 17 4k= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.3.1. 18 4k= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.3.1. 19 4l= ABC + 3TC + EFV, Male
HIV_RXC.1.
2.3.1. 20 4l= ABC + 3TC + EFV, Female
HIV_RXC.1.
2.3.2 Children 5 - 9 years currently on ART on second line regimen
HIV_RXC.1.
2.3.2. 1 5e=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.3.2. 2 5e=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.3.2. 3 5f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.3.2. 4 5f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.3.2. 5 5g= TDF + 3TC + EFV, Male
HIV_RXC.1.
2.3.2. 6 5g= TDF + 3TC + EFV, Female
HIV_RXC.1.
2.3.2. 7 5h=ABC + 3TC + EFV, Male
HIV_RXC.1.
2.3.2. 8 5h=ABC + 3TC + EFV, Female
HIV_RXC.1.
2.3.2. 9 5i=TDF + 3TC+ LPV/r, Male
HIV_RXC.1.
2.3.2. 10 5i=TDF + 3TC+ LPV/r, Female
HIV_RXC.1.
2.3.2. 11 Others, Male
HIV_RXC.1.
2.3.2. 12 Others, Female
HIV_RXC.1.
2.3.2. 13 5k= RAL + AZT + 3TC, Male
HIV_RXC.1.
2.3.2. 14 5k= RAL + AZT + 3TC, Female
HIV_RXC.1.
2.3.2. 15 5l= RAL + ABC + 3TC, Male
HIV_RXC.1.
2.3.2. 16 5l= RAL + ABC + 3TC, Female
HIV_RXC.1.
2.3.2. 17 5m = ABC + 3TC + DTG, Male
HIV_RXC.1.
2.3.2. 18 5m = ABC + 3TC + DTG, Female
HIV_RXC.1.
2.3.2. 19 5n= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.3.2. 20 5n= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.3.3 Children 5 - 9 years currently on ART on third line regimen
HIV_RXC.1.
2.3.3. 1 6a=DRV/r+RAL+AZT+3TC, Male
HIV_RXC.1.
2.3.3. 2 6a=DRV/r+RAL+AZT+3TC, Female
HIV_RXC.1.
2.3.3. 3 6b=DRV/r+RAL+TDF+3TC, Male
HIV_RXC.1.
2.3.3. 4 6b=DRV/r+RAL+TDF+3TC, Female
HIV_RXC.1.
2.3.3. 5 Others, Male
HIV_RXC.1.
2.3.3. 6 Others, Female
HIV_RXC.1.
2.3.3. 7 6c=DRV/r+DTG+AZT+3TC, Male
HIV_RXC.1.
2.3.3. 8 6c=DRV/r+DTG+AZT+3TC, Female
HIV_RXC.1.
2.3.3. 9 6f= DRV/r + DTG + ABC + 3TC, Male
HIV_RXC.1.
2.3.3. 10 6f= DRV/r + DTG + ABC + 3TC, Female
HIV_RXC.1.
2.4 Children aged 10-14 yrs currently on ART 0 0 0
HIV_RXC.1.
2.4.1 Children 10 - 14 years currently on ART on first line regimen
HIV_RXC.1.
2.4.1. 1 4c = AZT-3TC-NVP, Male
HIV_RXC.1.
2.4.1. 2 4c = AZT-3TC-NVP, Female
HIV_RXC.1.
2.4.1. 3 4d = AZT-3TC-EFV, Male
HIV_RXC.1.
2.4.1. 4 4d = AZT-3TC-EFV, Female
HIV_RXC.1.
2.4.1. 5 4e= TDF-3TC-EFV, Male
HIV_RXC.1.
2.4.1. 6 4e= TDF-3TC-EFV, Female
HIV_RXC.1.
2.4.1. 7 4f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.4.1. 8 4f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.4.1. 9 4g=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.4.1. 10 4g=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.4.1. 11 Others, Male
HIV_RXC.1.
2.4.1. 12 Others, Female
HIV_RXC.1.
2.4.1. 13 4i= TDF + 3TC + DTG, Male
HIV_RXC.1.
2.4.1. 14 4i= TDF + 3TC + DTG, Female
HIV_RXC.1.
2.4.1. 15 4j= ABC +3TC + DTG, Male
HIV_RXC.1.
2.4.1. 16 4j= ABC +3TC + DTG, Female
HIV_RXC.1.
2.4.1. 17 4k= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.4.1. 18 4k= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.4.1. 19 4l= ABC + 3TC + EFV, Male
HIV_RXC.1.
2.4.1. 20 4l= ABC + 3TC + EFV, Female
HIV_RXC.1.
2.4.2 Children 10 - 14 years currently on ART on second line regimen
HIV_RXC.1.
2.4.2. 1 5e=ABC + 3TC + LPV/r, Male
HIV_RXC.1.
2.4.2. 2 5e=ABC + 3TC + LPV/r, Female
HIV_RXC.1.
2.4.2. 3 5f=AZT + 3TC + LPV/r, Male
HIV_RXC.1.
2.4.2. 4 5f=AZT + 3TC + LPV/r, Female
HIV_RXC.1.
2.4.2. 5 5g= TDF + 3TC + EFV, Male
HIV_RXC.1.
2.4.2. 6 5g= TDF + 3TC + EFV, Female
HIV_RXC.1.
2.4.2. 7 5h=ABC + 3TC + EFV, Male
HIV_RXC.1.
2.4.2. 8 5h=ABC + 3TC + EFV, Female
HIV_RXC.1.
2.4.2. 9 5i=TDF + 3TC+ LPV/r, Male
HIV_RXC.1.
2.4.2. 10 5i=TDF + 3TC+ LPV/r, Female
HIV_RXC.1.
2.4.2. 11 Others, Male
HIV_RXC.1.
2.4.2. 12 Others, Female
HIV_RXC.1.
2.4.2. 13 5k= RAL + AZT + 3TC, Male
HIV_RXC.1.
2.4.2. 14 5k= RAL + AZT + 3TC, Female
HIV_RXC.1.
2.4.2. 15 5l= RAL + ABC + 3TC, Male
HIV_RXC.1.
2.4.2. 16 5l= RAL + ABC + 3TC, Female
HIV_RXC.1.
2.4.2. 17 5m = ABC + 3TC + DTG, Male
HIV_RXC.1.
2.4.2. 18 5m = ABC + 3TC + DTG, Female
HIV_RXC.1.
2.4.2. 19 5n= AZT + 3TC + DTG, Male
HIV_RXC.1.
2.4.2. 20 5n= AZT + 3TC + DTG, Female
HIV_RXC.1.
2.4.3 Children 10 - 14 years currently on ART on third line regimen
HIV_RXC.1.
2.4.3. 1 6a=DRV/r+RAL+AZT+3TC, Male
HIV_RXC.1.
2.4.3. 2 6a=DRV/r+RAL+AZT+3TC, Female
HIV_RXC.1.
2.4.3. 3 6b=DRV/r+RAL+TDF+3TC, Male
HIV_RXC.1.
2.4.3. 4 6b=DRV/r+RAL+TDF+3TC, Female
HIV_RXC.1.
2.4.3. 5 6c=DRV/r+DTG+AZT+3TC, Male
HIV_RXC.1.
2.4.3. 6 6c=DRV/r+DTG+AZT+3TC, Female
HIV_RXC.1.
2.4.3. 7 6d=DRV/r+DTG+TDF+3TC, Male
HIV_RXC.1.
2.4.3. 8 6d=DRV/r+DTG+TDF+3TC, Female
HIV_RXC.1.
2.4.3. 9 Others, Male
HIV_RXC.1.
2.4.3. 10 Others, Female
HIV_RXC.1.
2.4.3. 11 6f= DRV/r + DTG + ABC + 3TC, Male
HIV_RXC.1.
2.4.3. 12 6f= DRV/r + DTG + ABC + 3TC, Female
HIV_RXC_L
TF. Number of PLHIV who are documented as lost/lost to follow up
CDC_HIV_ Number of adults and children with HIV infection newly started on
RXN ART
CDC_HIV_
RXN. 1 < 1 year, Male
CDC_HIV_
RXN. 3 < 1 year, Female - non-pregnant
CDC_HIV_
RXN. 4 1 - 4 years, Male
CDC_HIV_
RXN. 6 1 - 4 years, Female - non-pregnant
CDC_HIV_
RXN. 7 5 - 9 years, Male
CDC_HIV_
RXN. 9 5 - 9 years, Female - non-pregnant
CDC_HIV_
RXN. 10 10 - 14 years, Male
CDC_HIV_
RXN. 12 10 - 14 years, Female - non-pregnant
CDC_HIV_
RXN. 13 15 - 19 years, Male
CDC_HIV_
RXN. 14 15 - 19 years, Female - pregnant
CDC_HIV_
RXN. 15 15 - 19 years, Female - non-pregnant
CDC_HIV_
RXN. 16 20 - 24 years, Male
CDC_HIV_
RXN. 17 20 - 24 years, Female - pregnant
CDC_HIV_
RXN. 18 20 - 24 years, Female - non-pregnant
CDC_HIV_
RXN. 19 25 - 49 years, Male
CDC_HIV_
RXN. 20 25 - 49 years, Female - pregnant
CDC_HIV_
RXN. 21 25 - 49 years, Female - non-pregnant
CDC_HIV_
RXN. 22 >= 50 years, Male
CDC_HIV_
RXN. 24 >= 50 years, Female - non-pregnant
Number of adults and children who are still on treatment at 12
HIV_RtR_1 months after initiating ART
HIV_RtR_1.
1 < 1 year, Male
HIV_RtR_1.
3 < 1 year, Female - non-pregnant
HIV_RtR_1.
4 1 - 4 years, Male
HIV_RtR_1.
6 1 - 4 years, Female - non-pregnant
HIV_RtR_1.
7 5 - 9 years, Male
HIV_RtR_1.
9 5 - 9 years, Female - non-pregnant
HIV_RtR_1.
10 10 - 14 years, Male
HIV_RtR_1.
12 10 - 14 years, Female - non-pregnant
HIV_RtR_1.
13 15 - 19 years, Male
HIV_RtR_1.
14 15 - 19 years, Female - pregnant
HIV_RtR_1.
15 15 - 19 years, Female - non-pregnant
HIV_RtR_1.
16 20 - 24 years, Male
HIV_RtR_1.
17 20 - 24 years, Female - pregnant
HIV_RtR_1.
18 20 - 24 years, Female - non-pregnant
HIV_RtR_1.
19 25 - 49 years, Male
HIV_RtR_1.
20 25 - 49 years, Female - pregnant
HIV_RtR_1.
21 25 - 49 years, Female - non-pregnant
HIV_RtR_1.
22 >= 50 years, Male
HIV_RtR_1.
24 >= 50 years, Female - non-pregnant

Number of persons on ART in the original cohort including those

HIV_NCC transferred in, minus those transferred out (net current cohort)
HIV_NCC.
1 < 1 year, Male
HIV_NCC.
3 < 1 year, Female - non-pregnant
HIV_NCC.
4 1 - 4 years, Male
HIV_NCC.
6 1 - 4 years, Female - non-pregnant
HIV_NCC.
7 5 - 9 years, Male
HIV_NCC.
9 5 - 9 years, Female - non-pregnant
HIV_NCC.
10 10 - 14 years, Male
HIV_NCC.
12 10 - 14 years, Female - non-pregnant
HIV_NCC.
13 15 - 19 years, Male
HIV_NCC.
14 15 - 19 years, Female - pregnant
HIV_NCC.
15 15 - 19 years, Female - non-pregnant
HIV_NCC.
16 20 - 24 years, Male
HIV_NCC.
17 20 - 24 years, Female - pregnant
HIV_NCC.
18 20 - 24 years, Female - non-pregnant
HIV_NCC.
19 25 - 49 years, Male
HIV_NCC.
20 25 - 49 years, Female - pregnant
HIV_NCC.
21 25 - 49 years, Female - non-pregnant
HIV_NCC.
22 >= 50 years, Male
HIV_NCC.
24 >= 50 years, Female - non-pregnant
Percentage of ART clients with undetectable viral load at 6 month
after initiation of ART
HIV_UVLC_ Number of adult and pediatric patients with an undetectable viral
6M load <1,000 copies/ml at 6 months
HIV_UVLC_
6M. 1 < 1 year, Male
HIV_UVLC_
6M. 3 < 1 year, Female - non-pregnant
HIV_UVLC_
6M. 4 1 - 4 years, Male
HIV_UVLC_
6M. 6 1 - 4 years, Female - non-pregnant
HIV_UVLC_
6M. 7 5 - 9 years, Male
HIV_UVLC_
6M. 9 5 - 9 years, Female - non-pregnant
HIV_UVLC_
6M. 10 10 - 14 years, Male
HIV_UVLC_
6M. 12 10 - 14 years, Female - non-pregnant
HIV_UVLC_
6M. 13 15 - 19 years, Male
HIV_UVLC_
6M. 14 15 - 19 years, Female - pregnant
HIV_UVLC_
6M. 15 15 - 19 years, Female - non-pregnant
HIV_UVLC_
6M. 16 20 - 24 years, Male
HIV_UVLC_
6M. 17 20 - 24 years, Female - pregnant
HIV_UVLC_
6M. 18 20 - 24 years, Female - non-pregnant
HIV_UVLC_
6M. 19 25 - 49 years, Male
HIV_UVLC_
6M. 20 25 - 49 years, Female - pregnant
HIV_UVLC_
6M. 21 25 - 49 years, Female - non-pregnant
HIV_UVLC_
6M. 22 >= 50 years, Male
HIV_UVLC_
6M. 24 >= 50 years, Female - non-pregnant
Number of adults and children who initiated ART in the 6 months
HIV_VLC_6 prior to the beginning of the reporting period with a viral load
M count at 6 month visit
HIV_VLC_6
M. 1 < 1 year, Male
HIV_VLC_6
M. 3 < 1 year, Female - non-pregnant
HIV_VLC_6
M. 4 1 - 4 years, Male
HIV_VLC_6
M. 6 1 - 4 years, Female - non-pregnant
HIV_VLC_6
M. 7 5 - 9 years, Male
HIV_VLC_6
M. 9 5 - 9 years, Female - non-pregnant
HIV_VLC_6
M. 10 10 - 14 years, Male
HIV_VLC_6
M. 12 10 - 14 years, Female - non-pregnant
HIV_VLC_6
M. 13 15 - 19 years, Male
HIV_VLC_6
M. 14 15 - 19 years, Female - pregnant
HIV_VLC_6
M. 15 15 - 19 years, Female - non-pregnant
HIV_VLC_6
M. 16 20 - 24 years, Male
HIV_VLC_6
M. 17 20 - 24 years, Female - pregnant
HIV_VLC_6
M. 18 20 - 24 years, Female - non-pregnant
HIV_VLC_6
M. 19 25 - 49 years, Male
HIV_VLC_6
M. 20 25 - 49 years, Female - pregnant
HIV_VLC_6
M. 21 25 - 49 years, Female - non-pregnant
HIV_VLC_6
M. 22 >= 50 years, Male
HIV_VLC_6
M. 24 >= 50 years, Female - non-pregnant
Number of adult and pediatric patients with an undetectable viral
HIV_SVLC load <1,000 copies/ml in the reporting period
HIV_SVLC.
1 < 1 year, Male
HIV_SVLC.
3 < 1 year, Female - non-pregnant
HIV_SVLC.
4 1 - 4 years, Male
HIV_SVLC.
6 1 - 4 years, Female - non-pregnant
HIV_SVLC.
7 5 - 9 years, Male
HIV_SVLC.
9 5 - 9 years, Female - non-pregnant
HIV_SVLC.
10 10 - 14 years, Male
HIV_SVLC.
12 10 - 14 years, Female - non-pregnant
HIV_SVLC.
13 15 - 19 years, Male
HIV_SVLC.
14 15 - 19 years, Female - pregnant
HIV_SVLC.
15 15 - 19 years, Female - non-pregnant
HIV_SVLC.
16 20 - 24 years, Male
HIV_SVLC.
17 20 - 24 years, Female - pregnant
HIV_SVLC.
18 20 - 24 years, Female - non-pregnant
HIV_SVLC.
19 25 - 49 years, Male
HIV_SVLC.
20 25 - 49 years, Female - pregnant
HIV_SVLC.
21 25 - 49 years, Female - non-pregnant
HIV_SVLC.
22 >= 50 years, Male
HIV_SVLC.
24 >= 50 years, Female - non-pregnant
Number of adult and pediatric ART patients at 12 month (yearly)
HIV_VLC viral load test in the reporting period
HIV_VLC. 1 < 1 year, Male
HIV_VLC. 3 < 1 year, Female - non-pregnant
HIV_VLC. 4 1 - 4 years, Male
HIV_VLC. 6 1 - 4 years, Female - non-pregnant
HIV_VLC. 7 5 - 9 years, Male
HIV_VLC. 9 5 - 9 years, Female - non-pregnant
HIV_VLC.
10 10 - 14 years, Male
HIV_VLC.
12 10 - 14 years, Female - non-pregnant
HIV_VLC.
13 15 - 19 years, Male
HIV_VLC.
14 15 - 19 years, Female - pregnant
HIV_VLC.
15 15 - 19 years, Female - non-pregnant
HIV_VLC.
16 20 - 24 years, Male
HIV_VLC.
17 20 - 24 years, Female - pregnant
HIV_VLC.
18 20 - 24 years, Female - non-pregnant
HIV_VLC.
19 25 - 49 years, Male
HIV_VLC.
20 25 - 49 years, Female - pregnant
HIV_VLC.
21 25 - 49 years, Female - non-pregnant
HIV_VLC.
22 >= 50 years, Male
HIV_VLC.
24 >= 50 years, Female - non-pregnant
HIV_NTR_S
4M Number of PLHIV who were assessed/screened for malnutrition
HIV_NTR_S
4M. 1 < 1 year, Male
HIV_NTR_S
4M. 3 < 1 year, Female - non-pregnant
HIV_NTR_S
4M. 4 1 - 4 years, Male
HIV_NTR_S
4M. 6 1 - 4 years, Female - non-pregnant
HIV_NTR_S
4M. 7 5 - 9 years, Male
HIV_NTR_S
4M. 9 5 - 9 years, Female - non-pregnant
HIV_NTR_S
4M. 10 10 - 14 years, Male
HIV_NTR_S
4M. 12 10 - 14 years, Female - non-pregnant
HIV_NTR_S
4M. 13 15 - 19 years, Male
HIV_NTR_S
4M. 14 15 - 19 years, Female - pregnant
HIV_NTR_S
4M. 15 15 - 19 years, Female - non-pregnant
HIV_NTR_S
4M. 16 20 - 24 years, Male
HIV_NTR_S
4M. 17 20 - 24 years, Female - pregnant
HIV_NTR_S
4M. 18 20 - 24 years, Female - non-pregnant
HIV_NTR_S
4M. 19 25 - 49 years, Male
HIV_NTR_S
4M. 20 25 - 49 years, Female - pregnant
HIV_NTR_S
4M. 21 25 - 49 years, Female - non-pregnant
HIV_NTR_S
4M. 22 >= 50 years, Male
HIV_NTR_S
4M. 24 >= 50 years, Female - non-pregnant
HIV_NTR_S Number of PLHIV that were nutritionally assessed and found to be
4MU.1 clinically undernourished - by age sex and pregnancy
HIV_NTR_S
4MU.1. 1 < 1 year, Male
HIV_NTR_S
4MU.1. 3 < 1 year, Female - non-pregnant
HIV_NTR_S
4MU.1. 4 1 - 4 years, Male
HIV_NTR_S
4MU.1. 6 1 - 4 years, Female - non-pregnant
HIV_NTR_S
4MU.1. 7 5 - 9 years, Male
HIV_NTR_S
4MU.1. 9 5 - 9 years, Female - non-pregnant

HIV_NTR_S
4MU.1. 10 10 - 14 years, Male

HIV_NTR_S
4MU.1. 12 10 - 14 years, Female - non-pregnant

HIV_NTR_S
4MU.1. 13 15 - 19 years, Male

HIV_NTR_S
4MU.1. 14 15 - 19 years, Female - pregnant

HIV_NTR_S
4MU.1. 15 15 - 19 years, Female - non-pregnant

HIV_NTR_S
4MU.1. 16 20 - 24 years, Male

HIV_NTR_S
4MU.1. 17 20 - 24 years, Female - pregnant

HIV_NTR_S
4MU.1. 18 20 - 24 years, Female - non-pregnant

HIV_NTR_S
4MU.1. 19 25 - 49 years, Male

HIV_NTR_S
4MU.1. 20 25 - 49 years, Female - pregnant

HIV_NTR_S
4MU.1. 21 25 - 49 years, Female - non-pregnant

HIV_NTR_S
4MU.1. 22 >= 50 years, Male

HIV_NTR_S
4MU.1. 24 >= 50 years, Female - non-pregnant
HIV_NTR_S Number of PLHIV that were nutritionally assessed and found to be
4MU.2 clinically undernourished - by nutritional status
HIV_NTR_S
4MU.2. 1 MAM
HIV_NTR_S
4MU.2. 2 SAM
Number of clinically undernourished PLHIV who received
HIV_NTR_S therapeutic or supplementary food by age sex and pregnancy
4MU_TF.1 status
HIV_NTR_S
4MU_TF.1.
1 < 1 year, Male
HIV_NTR_S
4MU_TF.1.
3 < 1 year, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
4 1 - 4 years, Male
HIV_NTR_S
4MU_TF.1.
6 1 - 4 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
7 5 - 9 years, Male
HIV_NTR_S
4MU_TF.1.
9 5 - 9 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
10 10 - 14 years, Male
HIV_NTR_S
4MU_TF.1.
12 10 - 14 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
13 15 - 19 years, Male
HIV_NTR_S
4MU_TF.1.
14 15 - 19 years, Female - pregnant
HIV_NTR_S
4MU_TF.1.
15 15 - 19 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
16 20 - 24 years, Male
HIV_NTR_S
4MU_TF.1.
17 20 - 24 years, Female - pregnant
HIV_NTR_S
4MU_TF.1.
18 20 - 24 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
19 25 - 49 years, Male
HIV_NTR_S
4MU_TF.1.
20 25 - 49 years, Female - pregnant
HIV_NTR_S
4MU_TF.1.
21 25 - 49 years, Female - non-pregnant
HIV_NTR_S
4MU_TF.1.
22 >= 50 years, Male
HIV_NTR_S
4MU_TF.1.
24 >= 50 years, Female - non-pregnant

HIV_NTR_S Number of clinically undernourished PLHIV who received

4MU_TF.2 therapeutic or supplementary food - by nutritional status
HIV_NTR_S
4MU_TF.2.
1 MAM
HIV_NTR_S
4MU_TF.2.
2 SAM
Number of persons provided with post-exposure prophylaxis (PEP)
HIV_PEP.1 for risk of HIV infection
HIV_PEP.1.
1 Non occupational risk
HIV_PEP.1.
2 Occupational risk
HIV_PE4HI
V Number of persons exposed for HIV infection eligible for PEP
HIV_PE4HI
V. 1 Non occupational risk
HIV_PE4HI
V. 2 Occupational risk
HIV_FP_Mt Number of PLHIV women aged 15-49 reporting the use of any
d method of modern family planning
HIV_FP_Mt
d. 1 Long acting
HIV_FP_Mt
d. 2 Short acting
HIV_FP_Ag Number of PLHIV women aged 15-49 reporting the use of any
e method of modern family planning by age
HIV_FP_Ag
e. 1 10 - 14 years
HIV_FP_Ag
e. 2 15 - 19 years
HIV_FP_Ag
e. 3 20 - 24 years
HIV_FP_Ag
e. 4 25 - 49 years
HIV_TBSC. Number of clients enrolled in HIV care who were screened for TB
1 during the reporting period
HIV_TBSC.
1. 1 < 1 year, Male
HIV_TBSC.
1. 3 < 1 year, Female - non-pregnant
HIV_TBSC.
1. 4 1 - 4 years, Male
HIV_TBSC.
1. 6 1 - 4 years, Female - non-pregnant
HIV_TBSC.
1. 7 5 - 9 years, Male
HIV_TBSC.
1. 9 5 - 9 years, Female - non-pregnant
HIV_TBSC.
1. 10 10 - 14 years, Male
HIV_TBSC.
1. 12 10 - 14 years, Female - non-pregnant
HIV_TBSC.
1. 13 15 - 19 years, Male
HIV_TBSC.
1. 14 15 - 19 years, Female - pregnant
HIV_TBSC.
1. 15 15 - 19 years, Female - non-pregnant
HIV_TBSC.
1. 16 20 - 24 years, Male
HIV_TBSC.
1. 17 20 - 24 years, Female - pregnant
HIV_TBSC.
1. 18 20 - 24 years, Female - non-pregnant
HIV_TBSC.
1. 19 25 - 49 years, Male
HIV_TBSC.
1. 20 25 - 49 years, Female - pregnant
HIV_TBSC.
1. 21 25 - 49 years, Female - non-pregnant
HIV_TBSC.
1. 22 >= 50 years, Male
HIV_TBSC.
1. 24 >= 50 years, Female - non-pregnant
HIV_TBPos Total number of HIV positive clients identified with active TB during
.1 reporting period
HIV_TBPos
.1. 1 < 15 years, Male
HIV_TBPos
.1. 2 < 15 years, Female
HIV_TBPos
.1. 3 >= 15 years, Male
HIV_TBPos
.1. 4 >= 15 years, Female
HIV_TBPos Total number of newly started ART clients with active TB in the
.2 reporting period
HIV_TBPos
.2. 1 < 15 years, Male
HIV_TBPos
.2. 2 < 15 years, Female
HIV_TBPos
.2. 3 >= 15 years, Male
HIV_TBPos
.2. 4 >= 15 years, Female
 Total number of newly enrolled ART clients initiated on LTBI
HIV_IPTE1 Treatment - IPT
HIV_IPTE1.
1 < 15 years, Male
HIV_IPTE1.
2 < 15 years, Female
HIV_IPTE1.
3 >= 15 years, Male
HIV_IPTE1.
4 >= 15 years, Female
Total number of newly enrolled ART clients initiated on LTBI
HIV_IPTE2 Treatment - 3HP
HIV_IPTE2.
1 < 15 years, Male
HIV_IPTE2.
2 < 15 years, Female
HIV_IPTE2.
3 >= 15 years, Male
HIV_IPTE2.
4 >= 15 years, Female
HIV_IPT_C Total number of PLHIV completed LTBI treatment (receiving
RX.1_Type IPT/3HP) during the reporting period
HIV_IPT_C
RX.1_Type.
1 IPT
HIV_IPT_C
RX.1_Type.
2 3HP
HIV_IPT_A Total number of adult PLHIV newly enrolled for ASM in the
SM.1.1 reporting period
HIV_IPT_A
SM.1.1. 1 Male
HIV_IPT_A
SM.1.1. 2 Female
HIV_IPT_A Total number of adult PLHIV currently on ASM in the reporting
SM.1.2 period
HIV_IPT_A
SM.1.2. 1 Male
HIV_IPT_A
SM.1.2. 2 Female
HIV_IPT_Pr Total number of clients identified for pre-Exposure prophylaxis in
eE.1 the reporting period
HIV_IPT_Pr
eE.1. 1 Sero discordant
HIV_IPT_Pr
eE.1. 2 Female sex worker
HIV_IPT_Pr Total number of clients newly enrolled on Pre-Exposure prohylaxis
eE.2 (PrEP) in the reporting period
HIV_IPT_Pr
eE.2. 1 Sero discordant
HIV_IPT_Pr
eE.2. 2 Female sex worker
HIV_IPT_Pr Total number of clients completed Pre-exposure prohylaxis (PrEP)
eE.3 in the reporting period
HIV_IPT_Pr
eE.3. 1 Sero discordant
HIV_IPT_Pr
eE.3. 2 Female sex worker
CDC_Mal Malaria
Mal_Pos Malaria positivity rate

Mal_Pos.1 Number of slides or RDT positive for malaria

Mal_Pos.1.
1 < 5 years, Male
Mal_Pos.1.
2 < 5 years, Female
Mal_Pos.1.
3 5 - 14 years, Male
Mal_Pos.1.
4 5 - 14 years, Female
Mal_Pos.1.
5 >= 15 years, Male
Mal_Pos.1.
6 >= 15 years, Female

Mal_DX. Total number of slides or RDT performed for malaria diagnosis

Number of women aged 30 - 49 screened with VIA for cervical
CA_VIA.1 cancer
CA_VIA.1.
1 Normal cervix
CA_VIA.1.
2 Precancerous lesion
CA_VIA.1.
3 Cancerous lesion
CA_SCCAL Number of women aged 30-49 year with cervical lesion received
_RX.1 treatment
CA_SCCAL
_RX.1. 1 Crayotherapy
CA_SCCAL
_RX.1. 2 LEEP
NCDC_DM Diabetes mellitus
NCDC_DM Total number of individuals screened for diabetes in the reporting
_Sc1 period
NCDC_DM
_Sc1. 1 40 - 49 years, Male
NCDC_DM
_Sc1. 2 40 - 49 years, Female
NCDC_DM
_Sc1. 3 50 - 59 years, Male
NCDC_DM
_Sc1. 4 50 - 59 years, Female
NCDC_DM
_Sc1. 5 60 - 69 years, Male
NCDC_DM
_Sc1. 6 60 - 69 years, Female
NCDC_DM
_Sc1. 7 >=70 years, Male
NCDC_DM
_Sc1. 8 >=70 years, Female
NCDC_DM Total number of individuals with raised blood sugar among
2 screened for diabetes in the reporting period
NCDC_DM
2. 1 40 - 49 years, Male
NCDC_DM
2. 2 40 - 49 years, Female
NCDC_DM
2. 3 50 - 59 years, Male
NCDC_DM
2. 4 50 - 59 years, Female
NCDC_DM
2. 5 60 - 69 years, Male
NCDC_DM
2. 6 60 - 69 years, Female
NCDC_DM
2. 7 >=70 years, Male
NCDC_DM
2. 8 >=70 years, Female
NCDC_DM
_NW3 Total number of new diabetic patients enrolled to care
NCDC_DM
_NW3. 1 < 40 years, Male
NCDC_DM
_NW3. 2 < 40 years, Female
NCDC_DM
_NW3. 3 40 - 49 years, Male
NCDC_DM
_NW3. 4 40 - 49 years, Female
NCDC_DM
_NW3. 5 50 - 59 years, Male
NCDC_DM
_NW3. 6 50 - 59 years, Female
NCDC_DM
_NW3. 7 60 - 69 years, Male
NCDC_DM
_NW3. 8 60 - 69 years, Female
NCDC_DM
_NW3. 9 >=70 years, Male
NCDC_DM
_NW3. 10 >=70 years, Female
NCDC_DM Total number of diabetic patients put on drug treatment in the
_N_Rx3. reporting period
NCDC_DM
_TP4 Total number of diabetic patients disaggregated by type
NCDC_DM
_TP4. 1 Diabetes mellitus Type I
NCDC_DM
_TP4. 2 Diabetes mellitus Type II
NCDC_DM
_TP4. 3 Gestational Diabetes mellitus (GDM)
NCDC_DM Total number of cohort diabetic patients enrolled to care six month
_Rx5. prior to the reporting month
NCDC_DM Total number of diabetic patients enrolled to care six month prior
_Rx6 to the reporting month
NCDC_DM
_Rx6. 1 Controlled
NCDC_DM
_Rx6. 2 Not controlled
NCDC_DM
_Rx6. 3 Lost to follow-up
NCDC_DM
_Rx6. 4 Died
NCDC_DM
_Rx6. 5 Transferred out
NCDC_HT Hypertension
NCDC_HT_ Total number of individuals screened for hypertension in the
Sc1 reporting period
NCDC_HT_
Sc1. 3 30 - 49 years, Male
NCDC_HT_
Sc1. 4 30 - 49 years, Female
NCDC_HT_
Sc1. 5 50 - 59 years, Male
NCDC_HT_
Sc1. 6 50 - 59 years, Female
NCDC_HT_
Sc1. 7 >=70 years, Male
NCDC_HT_
Sc1. 8 >=70 years, Female

Total number of individuals with raised blood pressure among

NCDC_HT2 screened for hypertension in the reporting period
NCDC_HT2
.3 30 - 49 years, Male
NCDC_HT2
.4 30 - 49 years, Female
NCDC_HT2
.5 50 - 59 years, Male
NCDC_HT2
.6 50 - 59 years, Female
NCDC_HT2
.7 >=70 years, Male
NCDC_HT2
.8 >=70 years, Female
NCDC_HT_
Nw3 Total number of new hypertensive patients enrolled to care
NCDC_HT_
Nw3. 1 < 30 years, Male
NCDC_HT_
Nw3. 2 < 30 years, Female
NCDC_HT_
Nw3. 3 30 - 49 years, Male
NCDC_HT_
Nw3. 4 30 - 49 years, Female
NCDC_HT_
Nw3. 5 50 - 59 years, Male
NCDC_HT_
Nw3. 6 50 - 59 years, Female
NCDC_HT_
Nw3. 7 >=70 years, Male
NCDC_HT_
Nw3. 8 >=70 years, Female
NCDC_HT_ Total number of hypertensive patients put on drug treatment in the
Nw_Rx3. reporting period
NCDC_HT_ Total number of hypertensive patients enrolled to care
Nw4 disaggregated by stage
NCDC_HT_
Nw4. 1 Stage I
NCDC_HT_
Nw4. 2 Stage II
NCDC_HT_
Nw4. 3 Severe HTN ( Including HTN emergency and urgency)
NCDC_HT_
Nw4. 4 Others
NCDC_HT_ Total number of cohort hypertensive patients enrolled to care six
Rx5. month prior to the reporting month
NCDC_HT_ Total number of hypertensive patients enrolled to care six month
Rx6 prior to the reporting month
NCDC_HT_
Rx6. 1 Controlled
NCDC_HT_
Rx6. 2 Not controlled
NCDC_HT_
Rx6. 3 Lost to follow-up
NCDC_HT_
Rx6. 4 Died
NCDC_HT_
Rx6. 5 Transferred out

NCDC_CVD Cardio Vascular Diseases

NCDC_CVD
1 Total number of patients assessed for CVD risk
NCDC_CVD
1. 1 CVD risk < 10%( Low)
NCDC_CVD
1. 2 CVD risk 10%-20%(Moderate)
NCDC_CVD
1. 3 CVD risk 20%-30%(High)
NCDC_CVD
1. 4 CVD risk >=30%(Very High)
 Number of patients with CVD risk >= 30% received treatment
CVD_RX.1. during the reporting period
HSQI Quality of health services
OPD_OPAP
C.1 Number of outpatient visits 860
OPD_OPAP
C.1. 1 < 5 years, Male 85
OPD_OPAP
C.1. 2 < 5 years, Female 97
OPD_OPAP
C.1. 3 5 - 10 years, Male 59
OPD_OPAP
C.1. 4 5 - 10 years, Female 68
OPD_OPAP
C.1. 5 11 - 19 years, Male 102
OPD_OPAP
C.1. 6 11 - 19 years, Female 101
OPD_OPAP
C.1. 7 20 - 29 years, Male 105
OPD_OPAP
C.1. 8 20 - 29 years, Female 63
OPD_OPAP
C.1. 9 30 - 45 years, Male 85
OPD_OPAP
C.1. 10 30 - 45 years, Female 17
OPD_OPAP
C.1. 11 46 - 65 years, Male 21
OPD_OPAP
C.1. 12 46 - 65 years, Female 42
OPD_OPAP
C.1. 13 >= 66 years, Male 12
OPD_OPAP
C.1. 14 >= 66 years, Female 3
FRM_HI_O
PAPC.1. Number of CBHI members visit made to HF in a month 79
HSQI_IPD_
AR Admission rate
IPD_AR.1. Number of inpatient admissions 4
Bed occupancy rate
IPD_BOR.1
. Length of stay (in days) in the reporting period
IPD_BOR.2
. Total number of beds
HSQI_IPD_
ALOS Average length of stay
IPD_ALS.1. Number of inpatient discharges
IPD_LoS.1. Total length of stay (in days) during discharge
HSQI_IPD_
IMR Inpatient mortality rate

IPD_IMR.1. Number of inpatient deaths in the reporting period

HSQI_BDB
_UBDU Proportion of blood units utilized from blood bank service
BDB_UBDR
.1. Total units of blood received from NBTS & regional blood banks
TtBD_UBD
T.1 Total number of units of blood transfused
TtBD_UBD
T.1. 1 direct family replacement
TtBD_UBD
T.1. 2 from blood bank
TtBD_UBD
T_SATIR Serious Adverse Transfusion Incidents and Reactions
UBDT_SATI Number of serious adverse transfusion incidents and reactions
R.1. occurred
HSQI_ERU
_MR Emergency unit/department mortality rate
ERU_MR.1 Total death in the emergency unit
ERU_MR.1.
1 < 15 years, Male
ERU_MR.1.
2 < 15 years, Female
ERU_MR.1.
3 >= 15 years, Male
ERU_MR.1.
4 >= 15 years, Female
ERU_ERA.1
. Total number of emergency unit attendances
RF_RFR.1 Number of people referred to other health facility
RF_RFR.1.
1 Emergency referral
RF_RFR.1.
2 Non-emergency referral

RTA_RTI.1 Number of road traffic injury cases dis aggregated by accident type
RTA_RTI.1.
1 Vehicle occupant
RTA_RTI.1.
2 Motor cyclist
RTA_RTI.1.
3 Pedestrian
RTA_RTI.1.
4 Others
HCSM_ED
A_TDR Tracer drug availability
EDA_TDR.1
. Availability of Amoxicillin 1 1 1
EDA_TDR.2
. Availability of Oral Rehydration Salt 1 1 1
EDA_TDR.3
. Availability of Zinc 1 1 1
EDA_TDR.4
. Availability of Gentamycine 1 1 1
EDA_TDR.5
. Availability of Cotrimoxazole 240 mg/ 5ml 1 1 1
EDA_TDR.6
. Availability of Magnesium Sulphate Injection 1 1 1
EDA_TDR.7
. Availability of Oxytocin Injection 1 1 1
EDA_TDR.8
. Availability of Enalapril 10mg tablets 1 1 1
EDA_TDR.9
. Availability of Medroxyprogesterone (depo) Injection 1 1 1
EDA_TDR.1
0. Availability of Glibenclamide 5mg 1 1 1
EDA_TDR.1
1. Availability of Adrenaline (Epinephrine) injection 1 1 1
EDA_TDR.1
2. Availability of Pentavalent DPT-Hep-Hib Vaccine 1 1 1
EDA_TDR.1
3. Availability of Glucose 40% 1 1 1
EDA_TDR.1
4. Availability of Dextrose in normal saline 1 1 1
EDA_TDR.1
5. Availability of Ferrous Sailt plus Folic Acid 1 1 1
EDA_TDR.1
6. Availability of Ciprofloxacin 500 mg tablet 1 1 1
EDA_TDR.1
7. Availability of Ceftriaxone 1 gm injection 1 1 1
EDA_TDR.1
8. Availability of Hydralazine injection 1 1 1
EDA_TDR.1
9. Availability of TDF/3TC/EFV adult 1 1 1
EDA_TDR.2
0. Availability of TB (RHZE/RH) patient kit 1 1 1
EDA_TDR.2
1. Availability of Tetanus antitoxine (TAT) 1 1 1
EDA_TDR.2
2. Availability of Tetracycline Eye Ointment 1 1 1
EDA_TDR.2
3. Availability of Arthemisin / Lumphantrine 1 1 1
EDA_TDR.2
4. Availability of Implanon NXT 1 1 1
EDA_TDR.2
5. Availability of Artesuante injection 1 1 1
HCSM_Dis
_PrDF Percentage of Clients with 100% prescribed drugs filled 97.8
Dis_PrDF.1
. Number of clients who received 100% of prescribed drugs 841
Dis_DPrR.1
. Total number of clients who received prescriptions 860
EBDM Evidence based decision making
 Proportion of facilities which have done LQAS 0 0 100
DQ_DA1. Did the HF conduct LQAS for service report? 1
DQ_DA.1.1
. LQAS first score for service report 90
DQ_DA.1.2
. LQAS last score for service report 90
DQ_DA2. Did the HF conduct LQAS for OPD report? 1
DQ_DA.2.1
. LQAS first score for OPD report 90
DQ_DA.2.2
. LQAS last score for OPD report 90
DQ_DA3. Did the HF conduct LQAS for IPD report? 1
DQ_DA.3.1
. LQAS first score for IPD report 90
DQ_DA.3.1
. LQAS last score for IPD report 90
Tikemet Tahesas Yekatit Megabit Miazia Genbot
2012 Hidar 2012 2012 Tir 2012 2012 2012 2012 2012 Sene 2012 Total

190 192 219 220 281 266 230 233 212 2408

137 114 98 100 120 134 84 103 100 1206

30 32 11 24 49 39 29 22 22 328

70 40 31 49 39 49 30 42 42 466

22 26 39 21 19 10 19 22 30 246

15 16 17 6 13 36 6 17 6 166

53 78 121 120 161 132 146 130 112 1202

20

20 19 21 31 69 51 49 32 31 373

22 29 31 51 57 59 29 21 52 403

11 20 41 30 24 11 49 52 20 278

10 28 8 11 11 19 25 9 128

190 192 219 220 281 266 230 233 212 2408

137 114 98 100 120 134 84 103 100 1206

40 13 10 18 17 49 10 16 5 210

90 80 77 72 90 80 74 81 80 856

7 21 11 10 13 5 6 15 137

53 78 121 120 161 132 146 130 112 1202

20 11 7 21 34 24 50 21 29 280

22 50 87 85 110 89 50 97 66 718

11 17 27 14 17 19 46 12 17 204

0 0 0 0 148.4 0 289.7 189.3 608.3 1235.7

5 10 7 21 43

3 2 5

5 2 2 12 21

5 5 2 12

5 5

5 10 7 21 43

5 8 7 17 37

2 4 6

9 7 10 4 9 3 12 12 69

3 7 10 4 3 5 2 37

3 7 10 4 3 4 2 36

1 1
64 80 74 77 81 69 79 72 69 751

61 80 63 77 60 59 10 72 2 562

3 11 21 10 69 67 189

64 80 74 88 81 69 79 72 69 762

3 4

21 30 11 40 49 39 10 12 2 270

43 50 63 48 32 27 69 60 67 488

20 28 40 41 51 39 40 32 69 410

1 1

8 10 11 17 29 20 9 2 29 159

12 18 29 24 22 19 31 30 39 250

64 89 101 90 97 69 89 69 803

64 89 101 90 97 69 89 69 803

64 89 101 90 97 69 89 69 793

25

64 89 101 90 97 69 89 69 768

19 42 49 47 41 49 42 45 42 440

0 0 0 0 0 0 0 0 0 0
39 42 49 47 41 49 42 45 42 460

11 11

45 52 69 57 41 85 62 62 52 602

45 52 69 57 41 85 52 55 52 585

5 5

10 2 12

0 6 5 7 7 5 0 0 6 39

2 3 3 5 2 4 22

1 1

2 3 1 3 2 2 16

2 1 3

2 2

4 2 4 2 3 2 17

2 1 2 1 1 7

2 1 2 1 2 2 10
 6 5 7 7 5 6 39

6 5 7 7 5 6 39

20 11 11 21 20 12 22 129

4 10 10 2 2 30

20 7 11 11 10 10 20 99
20 11 15 21 20 12 22 133

76 91 190 101 109 89 72 130 929

31 49

1 1

1 1 1 0 0 3

0 0 0 0 0 0 0 0 0 0
19 13 11 18 36 26 44 239

26 20 19 2 7 30 24 33 267

19 28 21 24 5 21 23 13 15 255

26 20 19 2 5 20 30 24 38 290

19 28 21 21 5 21 23 13 15 252

26 20 19 5 20 30 24 38 288

19 28 21 10 25 21 23 13 15 261

19 28 24 22 25 21 23 13 15 251
26 20 19 32 27 20 30 24 8 312

32 23 17 23 25 25 25 13 27 298

20 29 14 40 20 20 11 9 30 230

20 29 14 40 13 16 11 9 30 219

391 3 2 15 1 2 5 1 420

26 80 114 32 27 20 30 24 38 531

30 71 74 50 66 19 49 62 22 529
40 80 40 77 22 69 59 72 69 586
20 50 37 30 14 10 3 12 12 239
10 10 15 10 10 5 2 4 2 78
5 5 4 5 1 2 27

9.5 51.9 62.1 18.2 18.2 23.5 42.1 289.7

19 13 11 18 36 26 44 239

20 20 20 20 40 30 60 300

1 7 9 2 4 4 16 61

0 0 0 0 0 0 4.9 0 0 4.9

77 71 40 72 65 42 78 50 80 853

77 71 40 72 65 42 80 50 80 855

2 2

9.5 2.7 0 0 3 0 4.9 0 0 22

19 71 40 72 65 42 78 50 80 763

20 72 40 72 66 42 80 50 80 769
 1 1 1 2 6

0 0 0 8.3 0 0 0 0 0 8.3

58 43 36 55 52 45 55 37 65 640

58 43 36 60 52 45 55 37 65 645

9.5 20.2 0 18.2 13.3 27.6 0 0 0 123

19 71 40 72 65 42 80 50 80 764

20 80 40 80 70 50 80 50 80 810

1 9 8 5 8 46

0 12.5 26.1 27.6 22.2 64.4 0 46.2 47.5 380.9

20 420 17 42 35 21 20 14 31 657

20 450 20 50 40 40 20 20 40 750

30 3 8 5 19 6 19 103

0 26.1 4.4 12.5 10.3 1.7 9.5 8.7 96.3

105 170 172 112 104 119 152 105 1249

105 200 180 120 110 120 160 110 1325

30 8 6 1 8 5 68

9.5 0 33.3 26.7 28.6 46.2 37.8 51.9 40 331.5

19 28 24 22 25 21 23 13 15 251

20 28 30 30 30 30 30 20 20 308

1 6 5 9 7 7 5 49
140 108 38 44 12 22 36 78 46 667

4 20 9 3 6 6 7 2 3 61

2 2 5

82 50 24 28 8 28 25 95 61 505

9 3 4 2 25 133

0 0 0 0 0 0 0 0
 19 32 19 27 29 32 22 224

697 363 341 422 863 245 254 462 365 5934

59 122 129 10 185 59 9 9 15 923

638 241 212 412 678 186 245 453 350 5011

771 713 423 682 950 336 354 1089 627 7878

148 194 129 20 185 59 9 15 1096

623 519 294 662 765 277 345 1089 612 6782

1 1 8

1 1 8

19 14 9 1 7 60

19 14 9 1 7 60

12 11 4 1 35

12 11 4 1 35
 12 11 4 1 35

14 9 26

235 6 155 255 155 96 188 69 1535

75 6 23 128 42 41 76 14 481

160 132 127 113 55 112 55 1054

235 6 155 255 155 96 188 69 1535

235 6 617

155 255 155 96 188 69 918

202 4 165 198 126 143 69 916

202 4 215

165 198 126 143 69 701

147 96 195 148 67 179 278 212 1599

40 87 2 2 79 129 62 523

107 96 108 146 65 100 149 150 1076

64 80 91 87 20 99 89 69 599

10 10

21 30 41 41 8 49 39 29 258

43 50 50 46 12 40 50 40 331

19 19

86 811 89 1320
 50 50

100 100

150 150

150 150

18 100 136

68 100 197

50 95

50 111

11 100

30 122

20 89 109
112 705 446 90 163 109 89 72 1911

100 100

150 70 220

18 10 6 34

8 100 100 5 213

13 130 35 40 25 9 29 12 311

21 50 25 18 126

13 96 51 50 31 60 30 30 383

17 11 25 8 75

31 30 130 70 40 30 30 420

7 20 27

2 2
198 1516 446 450 151 109 89 72 3490

86 80 2 2 170

35 2 37

15 15

18 25 1 44

68 5 1 74
86 80 2 2 170
18 60 1 2 81
68 20 1 89

1 2 3

1 1

1 1

1 1
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
 0 0

14 14

10 1 2 13

2 1 3

1 1 2

1 1

3 1 4

1 1
1 1

1 1
379 51 301 110 496 182 1519

65 45 11 60 13 194

79 49 85 23 61 16 313

72 51 2 44 56 225

75 49 30 129 47 330

48 1 43 20 171 32 315

40 1 28 24 31 18 142

48 35 33 98 71 45 330

5 20 4 1 10 23 63

6 5 5 3 17 2 38

9 4 3 47 15 4 82

7 4 4 30 13 9 67

13 1 9 8 10 6 47

8 1 8 9 6 1 33

13 10 3 5 31
 3 1 4

4 1 2 7

2 2 1 5 10

2 2 4

1 2 3

1 2 3

51 6 74 79 10 220

51 12 6 3 79 10 161

29 5 5 3 52 9 103

21 6 1 25 1 54

1 1 2 4

306 220 109 635

234 34 109 79 456

170 30 87 79 366

39 2 9 50

20 1 8 29

5 1 5 11

18 3 13 98 52 184

9 2 7 70 50 138

7 1 2 28 2 40

1 1 2

1 3 4
853 1138 440 1376 574 1271 1221 815 8548

95 97 33 323 25 115 14 787

102 98 54 321 14 105 23 814

112 50 30 165 60 26 14 516

62 50 20 136 20 39 47 442

69 100 30 137 20 59 39 556

58 99 42 27 70 184 111 83 775

51 111 6 30 15 42 123 64 547

52 88 6 22 22 269 231 184 937

63 110 50 50 120 93 98 65 734

51 60 60 62 100 162 245 154 911

14 66 14 40 22 73 188 44 482

45 59 16 28 30 55 127 47 449

65 78 49 22 28 23 98 13 388

14 72 30 13 28 26 24 210

112 96 287

6 13 1 4 2 1 31
3.3 14.4 8.3 1.1 4.4 2.2 2.2 35.9

3 13 5 1 4 2 2 30

3 3 2 3 3 3 3 20

3 13 5 4 2 1 28
1 5 2 2 10
0 100 0 100
3 3

1 1

2 2

7 3 12 22
7 8 6 5 26

2 3 2 2 9

5 5 4 3 17

2 15 22 3 42

1 2 3

1 3 1 2 7

1 1 1 3

9 20 29

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12
 1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

1 1 1 1 1 1 1 1 1 12

95.2 21.6 94.9 100 97.4 95.3 99.3 99.5 100 901

812 400 1855 1350 2601 1211 2543 3009 1650 16272

853 1850 1954 1350 2670 1271 2560 3025 1650 18043
100 100 100 100 100 100 100 100 100 1000
1 1 1 1 1 1 1 1 1 10

90 90 95 90 90 90 85 90 90 900

90 90 95 95 95 95 90 90 90 920
1 1 1 1 1 1 1 8

90 90 80 80 80 90 90 90 90 870

90 90 90 90 90 90 90 90 90 900
1 1 3

90 90 90 90 90 90 90 90 95 905

90 90 90 90 90 90 90 90 95 905